Samsung Electronics Posts Eightfold Profit Surge Driven by AI Chip Demand 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Apple Turns 50: From Garage Startup to AI Crossroads 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
NEW YORK, Jan. 23, 2017 -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, today announced that Christopher U. Missling, PhD, President and Chief Executive Officer, will present a corporate overview at the Noble Capital Markets’ Thirteenth Annual Investor Conference at the Boca Raton Resort in Boca Raton, Florida, on Monday, January 30, at 2:30 p.m. EST.
A video and audio webcast of Anavex’s presentation will be available at noblemediasite.com and on the Company's web site at www.anavex.com. The webcast and presentation will be archived on Anavex’s website following the event.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq:AVXL) is a publicly traded biopharmaceutical company dedicated to the development of differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer. Anavex’s lead drug candidate, ANAVEX 2-73, recently completed successfully a Phase 2a clinical trial for Alzheimer’s disease. ANAVEX 2-73 is an orally available drug candidate that restores cellular homeostasis by targeting sigma-1 and muscarinic receptors and successfully completed Phase 1. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer’s disease. It has also exhibited anticonvulsant, anti-amnesic, neuroprotective and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy and others. The Michael J. Fox Foundation for Parkinson’s Research has awarded Anavex a research grant to develop ANAVEX 2-73 for the treatment of Parkinson’s disease to fully fund a preclinical study, which could justify moving ANAVEX 2-73 into a Parkinson’s disease clinical trial. ANAVEX 3-71, also targeting sigma-1 and M1 muscarinic receptors, is a promising preclinical drug candidate demonstrating disease modifications against the major Alzheimer’s hallmarks in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid and tau pathologies, and also with beneficial effects on neuroinflammation and mitochondrial dysfunctions. Further information is available at www.anavex.com and connect with the company on Twitter, Facebook and LinkedIn.
For Further Information: Anavex Life Sciences Corp. Research & Business Development Toll-free: 1-844-689-3939 Email: [email protected] Investors: Matthew Haines River East Investor Relations, LLC 917-733-9297 [email protected] Media: Dennis Dobson, Jr. Dobson Media Group 203-258-0159 [email protected]
